(Total Views: 288)
Posted On: 06/02/2021 5:06:01 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021,” POAI CEO J. Melville Engle was quoted in a recent article. “PeDAL brings together the key Helomics assets of real-world longitudinal data on 150,000 tumor drug response profiles and our clinically validated tumor assay with Quantitative Medicine’s active machine learning technology. We believe the PeDAL platform will revolutionize early discovery and allow our pharma partners to significantly improve the chances that new drugs will translate into the clinic, saving costs and time.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021,” POAI CEO J. Melville Engle was quoted in a recent article. “PeDAL brings together the key Helomics assets of real-world longitudinal data on 150,000 tumor drug response profiles and our clinically validated tumor assay with Quantitative Medicine’s active machine learning technology. We believe the PeDAL platform will revolutionize early discovery and allow our pharma partners to significantly improve the chances that new drugs will translate into the clinic, saving costs and time.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
